Key points are not available for this paper at this time.
In our study, we assessed the Prostate Imaging Reporting and Data System (PI-RADS), version 2.1, which is a continually developing and internationally acknowledged MRI-based scoring system used for evaluating the risk of prostate cancer. Conducted between April 2019 and December 2021, our prospective study focused on biological males with suspected or known prostate cancer, aiming to determine the effectiveness of PI-RADS 2.1 in conjunction with MRI features like lesion size, shape, and volume for detecting clinically significant prostate cancer. Apart from assessing the cancer yield in each PI-RADS category, another aspect of our work was to identify more objective, measurable criteria for lesion shape and volume, moving beyond the subjective parameters currently used in PI-RADS. We discovered that the likelihood of identifying clinically significant prostate cancer increases with higher PI-RADS categories and that quantifiable MRI features, such as lesion volume and measure of roundness, are predictors of significant cancer. Our findings also highlight that merging certain subcategories in PI-RADS might result in unnecessary biopsies. In conclusion, our research suggests that incorporating the objective lesion imaging criteria into patient care, alongside PI-RADS scores, could improve diagnostic accuracy. If validated in further studies, these objective measures could potentially be integrated into future iterations of PI-RADS, offering a more precise and reliable approach to prostate cancer detection and reducing unnecessary interventions.
Enis C. Yılmaz (Thu,) studied this question.